🇺🇸 FDA
Patent

US 9102940

RNAi modulation of SCAP and therapeutic uses thereof

granted A61PA61P1/00A61P1/16

Quick answer

US patent 9102940 (RNAi modulation of SCAP and therapeutic uses thereof) held by The Board of Regents of the University of Texas System expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61P, A61P1/00, A61P1/16, A61P3/00, A61P3/04